MVMerilyn S. Varghese

Merilyn S. Varghese

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Merilyn S. Varghese has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Dhruv S. Kazi

    Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA (D.S.K.).

    3 shared publications
  • Kristin M. Mattocks

    VA Central Western Massachusetts Healthcare System, Leeds, Massachusetts, USA; University of Massachusetts Medical School, Worcester, Massachusetts, USA

    3 shared publications
  • Lori A. Bastian

    Yale School of Medicine, New Haven, Connecticut, USA; VA Connecticut Healthcare System, West Haven, Connecticut, USA

    3 shared publications
  • Parul U. Gandhi

    Yale School of Medicine, New Haven, Connecticut, USA; VA Connecticut Healthcare System, West Haven, Connecticut, USA

    3 shared publications
  • Wen-Chih Wu

    Providence VA Medical Center

    3 shared publications
  • Cynthia A. Brandt

    Yale School of Medicine, New Haven, Connecticut, USA; VA Connecticut Healthcare System, West Haven, Connecticut, USA

    2 shared publications

Latest Publications

  • Open Access

    Cardiac Rehabilitation Utilization Among Veterans

    by Merilyn S. Varghese, Ling Han, Parul U. Gandhi, Melissa Skanderson, Wen-Chih Wu, Kariann R. Drwal, Matthew M. Burg, Dhruv S. Kazi, Allison E. Gaffey, Deborah R. Levy, et al.


  • Open Access

    Disparities in Geographic Access to Cardiac Rehabilitation Among Socially Vulnerable Communities

    by Edward W. Chen, Wen‐Chih Wu, Ling Han, Parul U. Gandhi, Lori A. Bastian, Cynthia A. Brandt, Kristin M. Mattocks, Joyce Oen‐Hsiao, Merilyn S. Varghese

    Background: There is a dearth of research examining geographic disparities in access to cardiac rehabilitation (CR). We evaluated whether disparities in geographic access to CR exist among socially vulnerable communities, using the Social Vulnerability Index (SVI). Methods: Among 3113 US counties, we investigated relationships between SVI and number of hospitals with CR per 100 000 adults, modeled with SVI as a linear variable, and SVI and distance to the nearest county with CR facilities, modeled using spline terms for SVI. We used multivariable zero‐inflated negative binomial regression modeling adjusted for county population, CR eligibility, percentage without health insurance, metropolitan status, and availability of existing health care infrastructure. We explored whether these relationships changed in the context of rurality. Results: After adjustment, as SVI increased by 1 percentile, number of hospitals with CR per 100 000 adults decreased by 1.2% ( P P =0.002) versus 2.2% in rural counties ( P <0.001). Conclusion: More socially vulnerable communities experienced worse geographic access to CR facilities. This access disparity intensified in rural communities. Our findings call for reducing barriers to CR access among socially vulnerable and rural communities, potentially through virtual or hybrid models of CR.


  • Cardiac Rehabilitation Among Veterans

    by Merilyn S. Md Varghese, Wen-Chih Wu, Kariann R. Drwal, Matthew M. Burg, Dhruv S. Md Kazi, Allison E. Gaffey, Kristin M. Mattocks, Cynthia A. Brandt, Lori A. Bastian, Parul U. Gandhi

    Purpose: Cardiac rehabilitation (CR) is a valuable secondary preventive intervention for Veterans given their increased risk of cardiovascular disease. Adults cared for in the Veterans Affairs (VA) healthcare system are a unique population that receives healthcare from the largest integrated care network in the United States. Yet, this group faces distinct challenges in utilizing CR. In this review, we evaluated the existing data regarding CR utilization and outcomes among U.S. Veterans. Review methods: A literature search was conducted using PubMed and Scopus for cardiac rehabilitation and U.S. Veterans. Summary: Veterans have 3 potential options for attending CR: in-person at their local VA medical centers, home-based CR through their local VA medical centers, and in-person at community CR centers. However, participation remains low. A significant barrier to participation is transportation to in-person CR. Home-based CR shows promise in addressing this barrier and has demonstrated resilience in the face of pandemic restrictions. Cardiac rehabilitation outcomes among Veterans who participate include improved exercise capacity, fewer depressive symptoms, and decreased mortality. Despite its benefits for secondary prevention among Veterans, there remains a paucity of data about the current uptake of CR, the impact of mental health on uptake, possible sex-based or racial disparities, and long-term outcomes.


  • Availability and Use of In-Person and Virtual Cardiac Rehabilitation Among US Medicare Beneficiaries: A Post-Pandemic Update

    by Merilyn S. Varghese, Yang Msc Song, Jiaman Xu, Issa MD Dahabreh, Alexis L. Md Beatty, Laurence S. Sperling, Gregg C. Fonarow, Steven J. Keteyian, Robert W. Md Yeh, Wen-Chih Wu, et al.


  • Open Access

    Impact of the COVID-19 pandemic on cardiology fellow echocardiography education at a large academic center

    by Merilyn S. Varghese, Jordan B. Strom, Joseph P. Kannam, Sarah E. Fostello, Marilyn F. Riley, Warren J. Manning

    In response to COVID-19 pandemic state restrictions, our institution deferred elective procedures from 3/15/2020 to 6/13/2020, and removed cardiology fellows from the echocardiography rotation to staff clinical services. We assessed the impact of the COVID-19 pandemic on fellow education and echocardiography volumes. Our institutional database was used to examine volumes of transthoracic (TTE), stress (SE), and transesophageal echocardiograms (TEE) from 7/1/2018 to 10/10/2020. Study volumes were compared in three intervals: pre-pandemic (7/1/2018- 3/14/2020), pandemic (3/15/2020–6/13/2020), and pandemic recovery (6/14/2020–10/10/2020). We examined weekly number of TTEs performed or interpreted by cardiology fellows during the study period, and compared these to the two previous academic years. Weekly TTE volume declined by 54% during the pandemic, and increased by 99% during pandemic recovery, (p < 0.05). SE and TEE revealed similar trends. A strong correlation between weekly TTE volume and inpatient admissions was observed during the study period (rs=0.67, p < 0.05). Weekly fellow TTE scans declined by 78% during the pandemic, with a 380% increase during pandemic recovery (p < 0.05). Weekly fellow TTE interpretations declined by 56% during the pandemic, with a 76% increase during pandemic recovery (p < 0.05). COVID restrictions between 3/15/2020- 6/14/2020 coincided with a marked decline in TTE, SE, and TEE volumes, with an increase similar to near pre-pandemic volumes during the pandemic recovery period. A similar decline with the onset of COVID restrictions, and increase to pre-restriction volumes thereafter was observed with fellow scans and interpretations, but total academic year fellow training volumes remained depressed. With the ongoing COVID-19 pandemic and rise of multiple variants, training programs may need to adjust fellows’ clinical responsibilities so as to support achievement of echocardiography training certification.

  • Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent Declines in Cardiac Rehabilitation Participation and Access Among US Medicare Beneficiaries

    by Merilyn S. Varghese, Alexis L. Beatty, Yang Song, Jiaman Xu, Laurence S. Sperling, Gregg C. Fonarow, Steven J. Keteyian, Kevin W. McConeghy, Joanne Penko, Robert W. Yeh, et al.

    Background: The impact of the COVID-19 pandemic on participation in and availability of cardiac rehabilitation (CR) is unknown. Methods: Among eligible Medicare fee-for-service beneficiaries, we evaluated, by month, the number of CR sessions attended per 100 000 beneficiaries, individuals eligible to initiate CR, and centers offering in-person CR between January 2019 and December 2021. We compared these outcomes between 2 periods: December 1, 2019 through February 28, 2020 (period 1, before declaration of the pandemic-related national emergency) and October 1, 2021 through December 31, 2021 (period 2, the latest period for which data are currently available). Results: In period 1, Medicare beneficiaries participated in (mean±SD) 895±84 CR sessions per 100 000 beneficiaries each month. After the national emergency was declared, CR participation sharply declined to 56 CR sessions per 100 000 beneficiaries in April 2020. CR participation recovered gradually through December 2021 but remained lower than prepandemic levels (period 2: 698±29 CR sessions per month per 100 000 beneficiaries, P =0.02). Declines in CR participation were most marked among dual Medicare and Medicaid enrollees and patients residing in rural areas or socially vulnerable communities. There was no statistically significant change in CR eligibility between the 2 periods. Compared with 2618±5 CR centers in period 1, there were 2464±7 in period 2 ( P <0.01). Compared with CR centers that survived the pandemic, 220 CR centers that closed were more likely to be affiliated with public hospitals, located in rural areas, and serve the most socially vulnerable communities. Conclusions: The COVID-19 pandemic was associated with a persistent decline in CR participation and the closure of CR centers, which disproportionately affected rural and low-income patients and the most socially vulnerable communities. Innovation in CR financing and delivery is urgently needed to equitably enhance CR participation among Medicare beneficiaries.


  • The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice

    by Merilyn S. Varghese, Chia-Liang Liu, Dhruv S. Kazi

    Purpose of Review The launch of new effective and safe cardiovascular drugs has produced large gains in health outcomes for several cardiovascular conditions. But this innovation comes at the cost of rapidly increasing pharmaceutical spending and high out-of-pocket costs. Recent Findings In the USA, manufacturers are able to set prices according to what the market will bear rather than value to patients or society, with a complicated system of discounts and rebates obscuring the final price borne by payors. Some of these costs are passed on to patients in the form of co-payments or co-insurance, making these effective but high-cost medications unaffordable for many patients. Orphan drugs developed to treat rare diseases—for which manufactures are presented substantial financial and regulatory benefits—are particularly problematic, as they typically enter the market at very high prices compared with drugs for other indications. Summary Systematic cost-effectiveness analyses from the healthcare sector or societal perspectives can help identify the value-based price of a medication at market entry as well as later in the lifecycle of the drug when more data on effectiveness and safety becomes available. Despite bipartisan support, legislative progress on drug pricing has been slow. Clinicians should know the cost of the drugs they prescribe frequently, use generics where feasible, and regularly discuss out-of-pocket costs with patients to pre-empt cost-related non-adherence.